drugset / Trial / NCT06482892
TP03HN106 in Patients With Critical Limb Ischemia
Phase 2
Recruiting
15 enrolled
Talengen Institute of Life Sciences, Shenzhen, P.R. China.
The First Affiliated Hospital of Soochow University · collab
NaSingle-groupOpen-labelTreatment
Summary
Critical limb ischemia (CLI) is the most severe ischemic stage in peripheral arterial disease (PAD) of the lower limbs, characterized by decreased walking ability, resting pain (lasting for more than 2 weeks), ulcers, and gangrene, which seriously affect the quality of life of patients. Some patients may even face amputation or death. Thrombosis is an important pathological feature of CLI. TP03HN106 can promote thrombolysis, thus having a therapeutic effect on CLI.
Timeline
- Start
- 2024-07-18
- Primary completion
- 2025-09-30
- Completion
- 2025-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TP03HN106 | Unknown | 10 iu/kg | Intravenous |
| Subject | TP03HN106 | Unknown | 20 iu/kg | Intravenous |
| Subject | TP03HN106 | Unknown | 30 iu/kg | Intravenous |
| Subject | TP03HN106 | Unknown | 40 iu/kg | Intravenous |
| Subject | TP03HN106 | Unknown | 50 iu/kg | Intravenous |